Sanctuary Advisors LLC Acquires Shares of 2,377 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sanctuary Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,377 shares of the biopharmaceutical company’s stock, valued at approximately $578,000.

A number of other large investors also recently modified their holdings of ALNY. Souders Financial Advisors lifted its stake in shares of Alnylam Pharmaceuticals by 1.0% in the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 36 shares in the last quarter. V Square Quantitative Management LLC lifted its position in Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 60 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 91 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $26,000. Finally, Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 1.1% in the first quarter. Daiwa Securities Group Inc. now owns 10,921 shares of the biopharmaceutical company’s stock worth $1,632,000 after purchasing an additional 116 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $283.32 on Tuesday. The stock has a market capitalization of $35.84 billion, a price-to-earnings ratio of -105.72 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The company’s fifty day simple moving average is $269.46 and its two-hundred day simple moving average is $213.46.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same quarter last year, the business posted ($2.21) earnings per share. Alnylam Pharmaceuticals’s revenue was up 107.0% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday. TD Cowen upped their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, August 30th. Finally, Citigroup lifted their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Six investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $285.95.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,148 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock valued at $13,595,460 over the last quarter. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.